NO934315L - Farmasoeytisk baerer - Google Patents

Farmasoeytisk baerer

Info

Publication number
NO934315L
NO934315L NO934315A NO934315A NO934315L NO 934315 L NO934315 L NO 934315L NO 934315 A NO934315 A NO 934315A NO 934315 A NO934315 A NO 934315A NO 934315 L NO934315 L NO 934315L
Authority
NO
Norway
Prior art keywords
giving
matrix
inert
active substance
pharmaceutically active
Prior art date
Application number
NO934315A
Other languages
English (en)
Other versions
NO934315D0 (no
NO306539B1 (no
Inventor
Bror Morein
Karin Loevgren
Original Assignee
Iscovent Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iscovent Ab filed Critical Iscovent Ab
Publication of NO934315D0 publication Critical patent/NO934315D0/no
Publication of NO934315L publication Critical patent/NO934315L/no
Publication of NO306539B1 publication Critical patent/NO306539B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/778—Nanostructure within specified host or matrix material, e.g. nanocomposite films
    • Y10S977/779—Possessing nanosized particles, powders, flakes, or clusters other than simple atomic impurity doping
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/918—Immunological
NO934315A 1991-05-31 1993-11-29 Medikamentbaerende partikkel og farmasöytisk blanding NO306539B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9101665A SE502569C2 (sv) 1991-05-31 1991-05-31 Användning av en immunologiskt inert matris av en sterol och saponiner som kan bilda sfäriska nanopartiklar med snäv storleksfördelning som läkemedelsbärare, partiklar, komposition samt kit
PCT/SE1992/000367 WO1992021331A1 (en) 1991-05-31 1992-06-01 Pharmaceutical carrier

Publications (3)

Publication Number Publication Date
NO934315D0 NO934315D0 (no) 1993-11-29
NO934315L true NO934315L (no) 1994-01-26
NO306539B1 NO306539B1 (no) 1999-11-22

Family

ID=20382906

Family Applications (1)

Application Number Title Priority Date Filing Date
NO934315A NO306539B1 (no) 1991-05-31 1993-11-29 Medikamentbaerende partikkel og farmasöytisk blanding

Country Status (13)

Country Link
US (1) US5603958A (no)
EP (1) EP0587659B1 (no)
JP (1) JPH07500084A (no)
KR (1) KR100227302B1 (no)
AT (1) ATE152620T1 (no)
AU (1) AU680807B2 (no)
CA (1) CA2103447C (no)
DE (1) DE69219600T2 (no)
ES (1) ES2103946T3 (no)
FI (1) FI110408B (no)
NO (1) NO306539B1 (no)
SE (1) SE502569C2 (no)
WO (1) WO1992021331A1 (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
EP1304041B8 (en) * 1996-07-08 2005-06-01 Idemitsu Kosan Co., Ltd. Feed composition for poultry
SI1037634T1 (sl) * 1997-12-08 2006-02-28 Altana Pharma Ag Peroralna dajalna oblika, ki obsega inhibitor protonske crpalke (npr. pantoprazol)
US6326507B1 (en) * 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
JP2002527367A (ja) * 1998-10-14 2002-08-27 コグニス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ナノスケールのステロールおよびステロールエステルの使用
JP4974414B2 (ja) * 1999-05-13 2012-07-11 ワイス・ホールディングズ・コーポレイション アジュバント混合製剤
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
US7713942B2 (en) 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
JP2004528321A (ja) * 2001-04-04 2004-09-16 ノルディック ワクチン テクノロジー アクティーゼルスカブ ステロールおよびサポニンを含むポリヌクレオチド結合複合体
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
EP1465615B1 (en) * 2002-01-15 2012-08-01 Trustees of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
EP1511468A1 (en) * 2002-06-10 2005-03-09 Elan Pharma International Limited Nanoparticulate sterol formulations and sterol combinations
JP2006503072A (ja) * 2002-10-02 2006-01-26 ノルディック ワクチン テクノロジー アクティーゼルスカブ ワクチン接種用組成物
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
PL1718283T3 (pl) 2004-01-22 2013-08-30 Univ Miami Miejscowe preparaty koenzymu Q10 i sposoby ich zastosowania
CN100339083C (zh) * 2004-02-24 2007-09-26 范敏华 一种黄体酮液体胶囊及其制备方法
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CN100398151C (zh) * 2005-02-18 2008-07-02 浙江大学 人参皂甙纳米微粒及其制备方法和用途
US20110098177A1 (en) * 2006-03-28 2011-04-28 Novus International Inc. Methods and compositions of plant micronutrients
US20080015218A1 (en) * 2006-07-12 2008-01-17 Novus International Inc. Antioxidant combinations for use in ruminant feed rations having a fat source
US8691843B2 (en) * 2006-07-12 2014-04-08 Novus International, Inc. Antioxidant combinations for use in ruminant feed rations
EP2094651A1 (en) * 2006-11-17 2009-09-02 Trustees Of Dartmouth College Synthesis and biological activities of new tricyclic-bis-enones (tbes)
EP2094242A4 (en) * 2006-11-17 2009-12-23 Novus Int Inc IN A MATRIX EMBEDDED COMPOSITIONS WITH ORGANIC ACIDS AND FATTY ACIDS
US8299046B2 (en) * 2006-11-17 2012-10-30 Trustees Of Dartmouth College Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
US20080119552A1 (en) * 2006-11-17 2008-05-22 Novus International Inc. Matrix-embedded compositions having organic acids and fatty acids
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
EP2094278B1 (en) * 2006-11-20 2017-04-05 Duecom Use of lipid containing particles comprising quillaja saponins for the treatment of cancer
AU2008228764B2 (en) 2007-03-22 2014-05-08 Berg Llc Topical formulations having enhanced bioavailability
CN101790305A (zh) * 2007-07-03 2010-07-28 诺华丝国际股份有限公司 可发酵碳水化合物水平低的仔猪饲料配给
WO2009023845A2 (en) * 2007-08-15 2009-02-19 The Board Of Regents Of The University Of Texas System Combination therapy with synthetic triterpenoids and gemcitabine
US8404714B2 (en) * 2008-01-04 2013-03-26 Novus International, Inc. Combinations to improve animal health and performance
MX2010007610A (es) 2008-01-11 2010-12-14 Reata Pharmaceuticals Inc Triterpenoides sinteticos y metodos de uso en el tratamiento de enfermedad.
WO2009126764A1 (en) 2008-04-11 2009-10-15 Cytotech Labs, Llc Methods and use of inducing apoptosis in cancer cells
AU2009237578C1 (en) 2008-04-18 2014-12-04 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
US8071632B2 (en) * 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
MX339476B (es) 2008-04-18 2016-05-27 Reata Pharmaceuticals Inc Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
PL2271658T3 (pl) * 2008-04-18 2017-05-31 Reata Pharmaceuticals, Inc. Przeciwutleniające modulatory zapalenia: c-17 homologowane pochodne kwasu oleanolowego
NZ588710A (en) 2008-04-18 2012-12-21 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
EP2309860B1 (en) * 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
KR20180018833A (ko) 2009-05-11 2018-02-21 베르그 엘엘씨 외대사 변환인자, 다차원 세포내 분자 또는 환경 영향인자를 사용하여 종양성 장애를 치료하는 방법
US20110020914A1 (en) * 2009-07-24 2011-01-27 Novus International Inc Methods for enhancing growth of organisms in an aqueous growth medium
SG183508A1 (en) * 2010-03-12 2012-10-30 Berg Pharma Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
ES2762451T3 (es) 2011-04-04 2020-05-25 Berg Llc Tratamiento de tumores del sistema nervioso central con coenzima Q10
PE20140628A1 (es) 2011-06-17 2014-05-30 Berg Llc Composiciones farmaceuticas inhalables
ES2673957T5 (es) 2011-10-03 2021-12-15 Croda Int Plc Nanopartículas, procedimiento para la preparación y utilización de las mismas como portadoras de moléculas anfipáticas o hidrofóbicas en el campo de la medicina, incluyendo el tratamiento del cáncer, y compuestos de tipo alimentario
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
BR112015025424A2 (pt) 2013-04-08 2017-07-18 Berg Llc tratamento de câncer usando terapias de combinação de coenzima q10
AU2014315186B2 (en) 2013-09-04 2020-02-27 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme Q10
CN110198718B (zh) 2016-11-08 2023-01-10 里亚塔医药控股有限责任公司 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3775783D1 (de) * 1986-01-14 1992-02-20 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
EP0368992B1 (en) * 1988-05-31 1995-02-15 Biotechnology Australia Pty. Ltd. Actions of hormones
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
US5077057A (en) * 1989-04-05 1991-12-31 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
GB8919819D0 (en) * 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity

Also Published As

Publication number Publication date
DE69219600T2 (de) 1997-10-02
US5603958A (en) 1997-02-18
CA2103447A1 (en) 1992-12-01
NO934315D0 (no) 1993-11-29
SE9101665D0 (sv) 1991-05-31
WO1992021331A1 (en) 1992-12-10
DE69219600D1 (de) 1997-06-12
AU1925192A (en) 1993-01-08
JPH07500084A (ja) 1995-01-05
AU680807B2 (en) 1997-08-14
EP0587659A1 (en) 1994-03-23
KR100227302B1 (ko) 1999-11-01
SE502569C2 (sv) 1995-11-13
ATE152620T1 (de) 1997-05-15
FI935314A (fi) 1993-11-29
CA2103447C (en) 1999-03-16
SE9101665L (sv) 1992-12-01
EP0587659B1 (en) 1997-05-07
ES2103946T3 (es) 1997-10-01
FI935314A0 (fi) 1993-11-29
NO306539B1 (no) 1999-11-22
FI110408B (fi) 2003-01-31

Similar Documents

Publication Publication Date Title
ATE152620T1 (de) Pharmazeutischer träger
MY118371A (en) Tetrahydrolipstatin containing compositions
ES2187201T3 (es) Empleo de esteroles y de esterolesteres a nanoescala.
CA2326485A1 (en) Anticancer compositions
ES2243229T3 (es) Formulaciones de particulas de hidrogel.
CA2231195A1 (en) Sustained release matrix for high-dose insoluble drugs
ATE55243T1 (de) Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung.
HUP0104230A2 (hu) Eljárás inhalációs adagolásra alkalmas hatóanyagszemcsék szuszpenzióinak előállítására
NO974404D0 (no) Insufflasjonsbærer for medikamenter med kontrollert frigivelse
RU94032150A (ru) Лекарственное средство с замедленным высвобождением активно-действующего вещества
ES2126536B1 (es) "preparado farmaceutico para administracion intranasal y procedimientopara su produccion".
AR011080A1 (es) Composicion en polvo seco, proceso para su preparacion y uso de dicha composicion para la fabricacion del medicamento
IL114596A (en) Pharmaceutical compositions containing an active substance blended with a carrier process for preparation thereof and their use for preparation of inhalated drugs
DE59806734D1 (de) Mittel zur antitumortherapie
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
IL108071A0 (en) Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridines their preparation and pharmaceutical compositions containing them
TNSN05048A1 (en) Inhalation compositions with high drug ratios
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
IL152074A0 (en) Pharmaceutical preparations and their manufacture
BG105570A (en) Pharmaceutical compositions for modified release insulin sensitiser
DE69222295T2 (de) Pulverförmige pharmazeutische Zusammensetzung
AU2503900A (en) Sulfated phosphatidylinositols, their preparation and use
GB1468815A (en) Pharmaceutical compositions
ES2193072T3 (es) Empleo cosmetico o farmaceutico de jabones metalicos a manoescala.
DE69717279T2 (de) Mittel gegen malaria und babesia und diese enthaltende pfarmazeutische zubereitungen

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees